Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series (Q44723870)

5 December 2017

title

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series (English)

1 reference

5 December 2017

Razelle Kurzrock

1 reference

5 December 2017

Francis Giles

1 reference

Apostolia Maria Tsimberidou

5 December 2017

series ordinal

object named as

Apostolia-Maria Tsimberidou

1 reference

5 December 2017

Luis Fayad

0 references

author name string

Madeleine Duvic

series ordinal

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

5 December 2017

1 reference

5 December 2017

volume

100

1 reference

5 December 2017

1 reference

5 December 2017

page(s)

342-349

1 reference

Deoxycoformycin in the treatment of mature T-cell leukaemias

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

Hereditary Severe Combined Immunodeficiency and Adenosine Deaminase Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Pentostatin (2′-Deoxycoformycin, dCF) in Patients with Low-Grade (B-T-Cell) and Intermediate- and High-Grade (T-Cell) Malignant Lymphomas: Phase II Study of the EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

EORTC classification for primary cutaneous lymphomas: a comparison with the R.E.A.L. Classification and the proposed WHO Classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

A modified staging classification for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Prognostic factor analysis in mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Reporting outcomes in Hodgkin's disease and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Pentostatin therapy of T-cell lymphomas with cutaneous manifestations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Treatment of Langerhans cell histiocytosis with 2'-deoxycoformycin (2'-DCF).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Therapy of T cell lymphomas with pentostatin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Treatment of cutaneous T cell lymphoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11899

7 January 2021

Identifiers

DOI

10.1002/CNCR.11899

1 reference

5 December 2017

1 reference